. 2022 Feb 14;11(4):992. doi: 10.3390/jcm11040992

Table 5.

Therapies applied during the hospitalization in the studied cohort.

Variables. Units (N)	Low Risk (0–1)	Medium Risk (2–3)	High Risk (>4)	OMNIBUS p Value	p Value (for Post-Hoc Analysis)
Variables. Units (N)	n/N (% of Risk Category)	n/N (% of Risk Category)	n/N (% of Risk Category)	OMNIBUS p Value	p Value (for Post-Hoc Analysis)
Applied treatment and procedures
Systemic corticosteroid (1047)	212/376 (56.38%)	211/419 (50.36%)	129/252 (51.19%)	0.2021	N/A
Convalescent plasma (1047)	56/376 (14.89%)	32/419 (7.64%)	27/252 (10.71%)	0.0048	0.005 ^a 0.48885 ^b 0.6648 ^c
Tocilizumab (1047)	6/376 (1.6%)	2/419 (0.48%)	1/252 (0.4%)	0.2223	N/A
Remdesivir (1047)	68/376 (18.09%)	59/419 (14.08%)	32/252 (12.7%)	0.1312	N/A
Antibiotic (1047)	230/376 (61.17%)	264/419 (63.01%)	175/252 (69.44%)	0.09451	N/A

Categorized variables are presented as: a number with a percentage. Information about the numbers with valid values is provided in the left column. Abbreviations: N—valid measurements. n—number of patients with parameter above cut-off point. SD—standard deviation. N/A—non-applicable. ^a—low risk vs. medium risk. ^b—low risk vs. high risk. ^c—medium risk vs. high risk; Bold text—statistically significant values Bold text-statistically significant values.